Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 501-510

  Spencer, Thomas J ^a   Greenbaum, Michael ^b   Ginsberg, Lawrence D ^c   Murphy, William Rory ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Capstone Clinical Research   (United States)

^c Red Oak Psychiatry Associates   (United States)

^d Psychiatric Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; GUANFACINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHYSICAL EXAMINATION; PRESCHOOL CHILD; QUESTIONNAIRE; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VITAL SIGN;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GUANFACINE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 70449120823     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0152     Document Type: Article

References (31)

1. Adderal XR (package insert). Wayne (Pennsylvania): Shire US Inc., 2009.
2. Adler LA, Reingold LS, Morrill MS, Wilens TE: Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 8:409-415, 2006.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). Washington (DC): American Psychiatric Association.
4. Arnsten AF, Scahill L, Findling RL: Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit=hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 17:393-406, 2007.
5. Biederman J and Faraone SV: Attention-deficit hyperactivity disorder. Lancet 366:237-248, 2005.
6. Biederman J, Melmed RD, Patel A, McBurnett R, Konow J, Lyne A, Scherer N, for the SPD503 Study Group: A randomized, doubleblind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit=hyperactivity disorder. Pediatrics 121:e73-e84, 2008.
7. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A: Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 27:1253-1262, 2007.
8. Brown TE: Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports. J Child Adolesc Psychopharmacol 14:129-136, 2004.
9. Cantwell DP: Attention deficit disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:978-987, 1996.
10. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140-1146, 1995.
11. Concerta (package insert). Titusville (New Jersey): McNeil Pediatrics, 2009.
12. Connor DF, Barkley RA, Davis HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 39:15-25, 2000.
13. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE Jr, Palumbo D, Harris P, Sallee FR: Clonidine for attention-deficit=hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 39:15-25, 2008.
14. Dulcan M and the Work Group on Quality Issues: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit=hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36(Suppl 10):85S-121S, 1997. (Pubitemid 27435161)
15. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(Suppl 2):26S-49S, 2002.
16. Hazell PL and Stuart JE: A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886-894, 2003.
17. Horrigan JP and Barnhill LJ: Guanfacine for treatment of attentiondeficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5:215-223, 1995.
18. Hunt RD, Arnsten AFT, Asbell MD: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50-54, 1995.
19. Kisicki JC, Fiske K, Lyne A: Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther 29:1967-1979, 2007.
20. Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT: Attention deficit hyperactivity disorder and comorbid disorders: Issues of overlapping symptoms. Am J Psychiatry 152:1793-1799, 1995.
21. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP: Clonidine for attention-deficit=hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 47:180-188, 2008.
22. Popper CW: Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 5:157-166, 1995.
23. Sallee F, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, for the SPD503 Study Group: Guanfacine extended release in children and adolescents with attention-deficit=hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155-165, 2009.
24. Scahill L and Schwab-Stone M: Epidemiology of ADHD in schoolage children. Child Adolesc Psychiatr Clin N Am 9:541-555, vii, 2000.
25. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067-1074, 2001.
26. Shojaei AH, Chang R-K, Pennick M: Guanfacine extended release tablets as treatment for attention-deficit=hyperactivity disorder: formulation characteristics. Poster presented at the U.S. Psychiatric & Mental Health Congress, November 16-19, 2006, New Orleans, Louisiana.
27. Swanson JM, Flockhart D, Udrea D, Cantwell DP, Connor D, Williams L: Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301-304, 1995.
28. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179, 2001.
29. Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K: A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 29:617-625, 2007.
30. The Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 58:527-536, 2002.
31. Uhlén S and Wikberg JES: Delineation of rat kidneya2A- and a2Badrenoceptors with [3H]RX821002 radioligand binding: Computer modelling reveals that guanfacine is an a2A-selective compound. Eur J Pharmacol 202:235-243, 1991.